Grit Biotechnology Completes Series A+ Financing to Accelerate Development of its Tumor Infiltrating Lymphocyte (TIL) Therapy Pipeline
SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing. The financing was led by GL Ventures, the venture capital unit of Hillhouse Group, with participation from Apricot Capital and Junshi Biosciences (HKEX: 1877; SSE: 688180), as well as continued support from existing shareholders, Decheng Capital and Matrix Partners.
Grit Bio was founded in 2019. It is on track to bring the first TIL therapy to solid tumor patients in China. Over the past year, the company has assembled a team of seasoned experts in the cell therapy field whose expertise cover early development, manufacturing, registration and trial management. Its leading program - GT101, a genetically unmodified TIL therapy - is currently being tested at a multi-centered clinical trial in China for solid malignancies indications.
Grit Bio has established three technology platforms as the cornerstone for its TIL development - Stable Virus Producing Cell Line (StaViral) – a highly efficient T-cell editing platform, Immunueregulatory Target Finder (ImmuT Finder) – a discovery platform to identify T-cell optimization targets, Stemness TIL Expansion Technology (StemTexp) – a proprietary expansion method making TIL into a viable cell therapy product. The company is currently developing a potentially best-in-class next generation TIL therapy based on these platforms.
“We are fortunate to be surrounded by leading investors whose support will enable the acceleration of our lead program GT101 into clinical development as well as continue to develop our commercial footprint in China,” said Yarng Liu, Co-founder and CEO, Grit Bio. The funds raised will help Grit advance its lead program into the clinic and support the development of its rich preclinical pipeline. The company anticipates IND filing for GT101 in China early 2022, as well as development of its next generation TIL program in the coming years.
“It’s a really exciting time in the cell therapy space. And there is increasing market recognition for cell therapy as a mainstream cancer treatment. We believe Grit Bio is well positioned to leverage the market potential and develop TIL therapies to help solid tumor patients,” said GL Ventures.
About Grit Bio
About GL Ventures
About Apricot Capital
About Junshi Bioscience